2
Clinical Trials associated with EcoActive(Intralytix)A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections
The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated.
Start Date01 Dec 2005 |
Sponsor / Collaborator- |
100 Clinical Results associated with EcoActive(Intralytix)
100 Translational Medicine associated with EcoActive(Intralytix)
100 Patents (Medical) associated with EcoActive(Intralytix)
100 Deals associated with EcoActive(Intralytix)